MedTrace Logo

MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)

NCT00122226 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2006-04-25

No results posted yet for this study

Summary

This is a randomized prospective study into metabolic adverse events during different types of initial antiretroviral therapy in HIV-1-infected men.

Conditions

  • HIV Infections
  • HIV-Associated Lipodystrophy Syndrome

Interventions

DRUG

Lopinavir/ritonavir + zidovudine + lamivudine

DRUG

Lopinavir/ritonavir + nevirapine

Sponsors & Collaborators

Principal Investigators

  • S. A. Danner, MD, PhD · Free University Medical Center

  • P. Reiss, MD, PhD · Academic Medical Center, National AIDS Therapy Evaluation Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Completion
2008-07-31

Countries

  • Finland
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00122226 on ClinicalTrials.gov